SAFETY

More Than 90% of Patients Receiving OPSYNVI^® Remained on Therapy¹

Results from the double-blind study

Adverse reactions that occurred in ≥3% of patients treated with OPSYNVI^® (macitentan/
tadalafil)¹

	OPSYNVI® (n=107)	Macitentan Monotherapy (n=35)	Tadalafil Monotherapy (n=44)
Edema/fluid retention	21%	14%	16%
Anemia	19%	3%	2%
Headache	18%	17%	14%
Abdominal pain	7%	3%	14%
Hypotension	7%	0%	0%
Myalgia	6%	0%	5%
Nasopharyngitis	6%	3%	0%
Nausea	6%	0%	7%
Increased uterine bleeding	5%	0%	0%
Back pain	5%	3%	9%
Flushing	4%	6%	0%
Vomiting	4%	0%	5%
Palpitations	4%	3%	5%
Pain in extremity	3%	0%	7%
Epistaxis	3%	0%	0%

Discontinuations due to adverse events
among patients receiving OPSYNVI^® (macitentan/tadalafil) was 8%, most
frequently due to anemia and hemoglobin decreased (2% grouped) and peripheral
edema and peripheral swelling (2% grouped).

No new safety or tolerability signals emerged versus macitentan and tadalafil as individual components.^1,2

Review patient cases

and see if OPSYNVI^® is right for your patients with PAH

Patient Cases

More Than 90% of Patients Receiving OPSYNVI® Remained on Therapy1

More Than 90% of Patients Receiving OPSYNVI^® Remained on Therapy¹